

AMENDMENTS TO THE CLAIMS

- 1. (Currently amended)** A pharmaceutical composition comprising amorphous cefditoren pivoxil and a sucrose fatty acid ester, which is obtainable by mixing or wet-granulating particles containing amorphous cefditoren pivoxil with the sucrose fatty acid ester while amorphous cefditoren pivoxil maintains its particle state, wherein crystallization of the amorphous cefditoren pivoxil is inhibited in aqueous medium for a period of at least two days.
- 2. (Previously presented)** The pharmaceutical composition according to claim 1, wherein the weight ratio of the sucrose fatty acid ester to the cefditoren pivoxil is in a range of from 0.0008 to 0.816.
- 3. (Previously presented)** The pharmaceutical composition according to claim 1, which further comprises a pharmaceutically acceptable polymer.
- 4. (Previously presented)** The pharmaceutical composition according to claim 3, wherein the polymer is one or more water-soluble high polymers selected from the group consisting of hydroxypropylmethyl cellulose, methylcellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, and hydroxypropyl cellulose.
- 5. (Previously presented)** The pharmaceutical composition according to claim 3, wherein the weight ratio of the polymer to the cefditoren pivoxil is in a range of from 0.008 to 0.816.
- 6. (Previously presented)** The pharmaceutical composition according to claim 1, which further comprises one or more pharmaceutically acceptable additives.
- 7. (Previously presented)** The pharmaceutical composition according to claim 2, which further comprises a pharmaceutically acceptable polymer.

- 8. (Previously presented)** The pharmaceutical composition according to claim 7, wherein the polymer is one or more water-soluble high polymers selected from the group consisting of hydroxypropylmethyl cellulose, methylcellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, and hydroxypropyl cellulose.
- 9. (Previously presented)** The pharmaceutical composition according to claim 4, wherein the weight ratio of the polymer to the cefditoren pivoxil is in a range of from 0.008 to 0.816.
- 10. (Previously presented)** The pharmaceutical composition according to claim 7, wherein the weight ratio of the polymer to the cefditoren pivoxil is in a range of from 0.008 to 0.816.
- 11. (Previously presented)** The pharmaceutical composition according to claim 8, wherein the weight ratio of the polymer to the cefditoren pivoxil is in a range of from 0.008 to 0.816.
- 12. (Previously presented)** The pharmaceutical composition according to claim 2, which further comprises one or more pharmaceutically acceptable additives.
- 13. (Previously presented)** The pharmaceutical composition according to claim 3, which further comprises one or more pharmaceutically acceptable additives.
- 14. (Previously presented)** The pharmaceutical composition according to claim 4, which further comprises one or more pharmaceutically acceptable additives.
- 15. (Previously presented)** The pharmaceutical composition according to claim 7, which further comprises one or more pharmaceutically acceptable additives.
- 16. (Previously presented)** The pharmaceutical composition according to claim 8, which further comprises one or more pharmaceutically acceptable additives.

17. (Previously presented) The pharmaceutical composition according to claim 9, which further comprises one or more pharmaceutically acceptable additives.

18. (Previously presented) The pharmaceutical composition according to claim 10, which further comprises one or more pharmaceutically acceptable additives.

19. (Previously presented) The pharmaceutical composition according to claim 11, which further comprises one or more pharmaceutically acceptable additives.

20-31. (Cancelled)

32. (Previously presented) The pharmaceutical composition according to claim 1, wherein the composition is free from polysorbate 80.

33-38. (Cancelled)

39. (Previously presented) A pharmaceutical composition comprising amorphous cefditoren pivoxil and sucrose fatty acid ester, wherein the weight ratio of the sucrose fatty acid ester to the amorphous cefditoren pivoxil is in a range of from 0.0008 to 0.04, and wherein the composition is capable of retaining the amorphicity of said amorphous cefditoren pivoxil in aqueous medium for at least two days.

40. (Previously presented) A pharmaceutical composition comprising amorphous cefditoren pivoxil in combination with an amount of sucrose fatty acid ester that is effective to maintain said amorphous cefditoren pivoxil in an amorphous state in aqueous medium for a period of at least two days.

41. (Previously presented) The pharmaceutical composition according to claim 1, wherein the weight ratio of the sucrose fatty acid ester to the cefditoren pivoxil is in a range of from 0.0008 to 0.04.